Can Utepreva’s new device solve the biggest problem in endometrial cancer diagnosis?
Utepreva’s FDA-cleared endometrial sampler promises earlier cancer detection. Find out how this device could reshape diagnostics today.
Can Junction’s GRAIL tie-up do what clinical data alone could not for Galleri adoption?
Junction and GRAIL are expanding Galleri access, but can workflow integration overcome regulatory, reimbursement, and adoption hurdles? Read more.